

# Blepharitis Treatment Pipeline Review H2 2016

*Global Blepharitis Drugs and Companies Pipeline Review H2 2016*

PUNE, INDIA, September 19, 2016

/EINPresswire.com/ -- Summary

The report provides comprehensive information on the therapeutics under development for

Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects.

Drug profiles featured in the report undergoes periodic review following a stringent set of

processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Complete Report @ <https://www.wiseguyreports.com/reports/643474-blepharitis-pipeline-review-h2-2016>

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Blepharitis
- The report reviews pipeline therapeutics for Blepharitis by companies and universities/research



institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Blepharitis therapeutics and enlists all their major and minor projects
- The report assesses Blepharitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Blepharitis

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643474-blepharitis-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Blepharitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/643474-blepharitis-pipeline-review-h2-2016>

Table of Content

Blepharitis Overview 6

Therapeutics Development 7

Pipeline Products for Blepharitis - Overview 7

Blepharitis - Therapeutics under Development by Companies 8

Blepharitis - Pipeline Products Glance 9  
Late Stage Products 9  
Clinical Stage Products 10  
Early Stage Products 11  
Blepharitis - Products under Development by Companies 12  
Blepharitis - Companies Involved in Therapeutics Development 13  
Allergan Plc 13  
InSite Vision Incorporated 14  
Kala Pharmaceuticals, Inc. 15  
NicOx S.A. 16  
Quorum Innovations LLC 17  
Senju Pharmaceutical Co., Ltd. 18  
Blepharitis - Therapeutics Assessment 19  
Assessment by Monotherapy Products 19  
Assessment by Target 20  
Assessment by Mechanism of Action 22  
Assessment by Route of Administration 24  
Assessment by Molecule Type 26  
Drug Profiles 28  
AGN-195263 - Drug Profile 28  
Product Description 28  
Mechanism Of Action 28  
R&D Progress 28  
azithromycin - Drug Profile 29  
Product Description 29  
Mechanism Of Action 29  
R&D Progress 29  
azithromycin - Drug Profile 30  
Product Description 30  
Mechanism Of Action 30  
R&D Progress 30  
dexamethasone acetate - Drug Profile 31  
Product Description 31  
Mechanism Of Action 31  
R&D Progress 31  
fluticasone propionate - Drug Profile 33  
Product Description 33  
Mechanism Of Action 33  
R&D Progress 33  
ISV-405 - Drug Profile 34  
Product Description 34  
Mechanism Of Action 34  
R&D Progress 34

loteprednol etabonate - Drug Profile 36  
Product Description 36  
Mechanism Of Action 36  
R&D Progress 36  
Qi-305 - Drug Profile 39  
Product Description 39  
Mechanism Of Action 39  
R&D Progress 39  
Blepharitis - Dormant Projects 40  
Blepharitis - Product Development Milestones 41  
Featured News & Press Releases 41  
Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults 41

Buy now @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=643474](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643474)

Continued...

Contact Us:  
NORAH TRENT  
Partner Relations & Marketing Manager  
sales@wiseguyreports.com  
Ph: +1-646-845-9349 (US)  
Ph: +44 208 133 9349 (UK)□

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/345413981>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.